0.8423

12.74% 0.0952

After Hours: .85 0.0077 +0.91%

Briacell Therapeutics Corp (BCTX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Briacell Therapeutics Corp stock is traded at $0.8423, with a volume of 1.13M. It is up +12.74% in the last 24 hours and down -2.85% over the past month. BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Previous Close:

$0.7471

Open:

$0.7563

24h Volume:

1.13M

Relative Volume:

0.23

Market Cap:

$28.58M

Revenue:

Net Income/Loss:

$-6.00M

P/E Ratio:

-6.2952

EPS:

-0.1338

Net Cash Flow:

$-31.01M

1W Performance:

+39.85%

1M Performance:

-2.85%

6M Performance:

-41.51%

1Y Performance:

-82.91%

1-Day Range:

$0.74

$0.8423

1-Week Range:

$0.61

$0.8423

52-Week Range:

$0.4641

$5.97

Briacell Therapeutics Corp Stock (BCTX) Company Profile

Name

Briacell Therapeutics Corp

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(604) 921-1810

Address

3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER

Employee

Twitter

Next Earnings Date

2024-10-28

Latest SEC Filings

BCTX's Discussions on Twitter

Compare BCTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BCTX Briacell Therapeutics Corp	0.8423	28.58M	0	-6.00M	-31.01M	-0.1338
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-14-22	Initiated	H.C. Wainwright	Buy

Briacell Therapeutics Corp Stock (BCTX) Latest News

Nov 26, 2024

BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive - GlobeNewswire

Nov 26, 2024

BriaCell's Breast Cancer Therapy Shows 13.4-Month Survival Rate in Phase 2 Trial | BCTX Stock News - StockTitan

Nov 26, 2024

Nov 25, 2024

BriaCell announces board member resignation - Investing.com

Nov 25, 2024

BriaCell Provides Update to its Board of Directors - GlobeNewswire

Nov 25, 2024

BriaCell Therapeutics Director Marc Lustig Steps Down from Board, Effective Immediately | BCTXW Stock News - StockTitan

Nov 25, 2024

Nov 24, 2024

BriaCell Therapeutics Corp. (BCT.TO) latest stock news and headlines - Yahoo Finance UK

Nov 24, 2024

Nov 22, 2024

U.S. Dollar/Rwanda Rwanda Francs (USDRWF) QuotePress Release - The Globe and Mail

Nov 22, 2024

Nov 21, 2024

BCTXBriacell Therapeutics Corp. Common Shares Latest Stock News & Market Updates - StockTitan

Nov 21, 2024

BriaCell begins phase 1/2 trial of Bria-OTS™ for breast cancer | 2024-11-21 | Investing News - Stockhouse Publishing

Nov 21, 2024

BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study - GlobeNewswire

Nov 21, 2024

BriaCell Launches Phase 1/2 Trial of Next-Gen Breast Cancer Immunotherapy | BCTX Stock News - StockTitan

Nov 21, 2024

Nov 20, 2024

Global X Equal Wght CDN Oil Gas Indx ETF (NRGY-T) QuotePress Release - The Globe and Mail

Nov 20, 2024

Global X Equal Weight Canadian Groceries & Stapl (MART-T) QuotePress Release - The Globe and Mail

Nov 20, 2024

Nov 13, 2024

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13 - StockTitan

Nov 04, 2024

Nov 01, 2024

BriaCell Therapeutics Faces Uncertain Financial Future - TipRanks

Nov 01, 2024

Oct 28, 2024

BriaCell Therapeutics Corp. Reports Earnings Results for the Full Year Ended July 31, 2024 - Marketscreener.com

Oct 28, 2024

Oct 22, 2024

BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns - Seeking Alpha

Oct 22, 2024

BriaCell reports survival data from Phase 2 study | 2024-10-22 | Investing News - Stockhouse Publishing

Oct 22, 2024

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data - GlobeNewswire

Oct 22, 2024

Oct 16, 2024

You might want to take a look at BriaCell Therapeutics Corp (BCTX) now - SETE News

Oct 16, 2024

Oct 15, 2024

BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study - GlobeNewswire

Oct 15, 2024

BriaCell Therapeutics advances Phase 3 MBC clinical study | 2024-10-15 | Investing News - Stockhouse Publishing

Oct 15, 2024

BCTX’s 52-Week Rollercoaster: From $0.46 to $5.97 – What’s Next for Investors? - The InvestChronicle

Oct 15, 2024

BriaCell stock gains after trial update (NASDAQ:BCTX) - Seeking Alpha

Oct 15, 2024

Extendicare Inc. - Baystreet.ca

Oct 15, 2024

BriaCell Therapeutics Corp. - Baystreet.ca

Oct 15, 2024

Oct 14, 2024

Analyzing BriaCell Therapeutics Corp (BCTX) After Recent Trading Activity - Knox Daily

Oct 14, 2024